Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MSD’s 21-Valent Pneumococcal Shot Nears Japan Approval; Male Use of Silgard 9 Cleared
A Japanese health ministry panel on July 24 endorsed a series of label expansions and one new vaccine from MSD - a 21-valent pneumococcal conjugate jab known as Capvaxive overseas - paving the way for their imminent approval. The Pharmaceutical…
To read the full story
Related Article
- MSD Launches 21-Valent Pneumococcal Vaccine Capvaxive in Japan
October 30, 2025
- Japan Approves 3 New Drugs, Expands Label for Enhertu, Silgard 9 and More
August 26, 2025
- Japan Approves MSD’s 21-Valent Pneumococcal Vaccine
August 8, 2025
- Japan Panel to Review MSD’s 21-Valent Pneumococcal Shot, Silgard 9 for Male Use and More Label Expansions
July 18, 2025
- MSD Files Silgard 9 for Male Use in Japan
November 18, 2024
- Enhertu Filed for HER2 Low or Ultralow Breast Cancer in Japan
October 7, 2024
- Opdivo-Yervoy Filed for 1st Line Use in MSI-H Colorectal Cancer in Japan
September 13, 2024
- MSD Seeks Japan Nod for 21-Valent Pneumococcal Jab for Adults
August 13, 2024
REGULATORY
- Japan Enacts Revised Immunization Act, Opens Way for RSV Antibodies under NIP
July 27, 2026
- PMDA Sees Drop in Japan-China Bilateral Regulatory Exchanges
July 27, 2026
- MHLW to Hear Patient Groups on OTC-Like Drug Charge Exemptions
July 27, 2026
- Japan to Clarify Non-Clinical Data Waivers for Repurposed Drugs, Ease Sakigake Rules
July 24, 2026
- Share of Negative-Margin WPPs Rises to 6.9%, Wholesalers Cite Communication Gap
July 24, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…